Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus
BMC Infectious Diseases volume 4, Article number: 14 (2004)
In our recent article , we did not declare the patent rights related to stampidine technology. Since they may potentially be viewed as non-financial competing interests despite the fact our employer is a non-profit public charity, we are now providing the following supplemental information:
FMU, AOV and HET are employees of Parker Hughes Institute, which has applied for a patent for the use of stampidine in the treatment of haemorrhagic fever. Parker Hughes Institute currently holds patents for the use of stampidine in other clinical conditions, with FMU listed as an inventor.
Uckun FU, Petkevich AS, Vassilev AO, Tibbles HE, Titov LP: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis. 2004, 4: 1-10.1186/1471-2334-4-1.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/4/14/prepub
The online version of the original article can be found at 10.1186/1471-2334-4-1
About this article
Cite this article
Uckun, F.M., Petkevich, A.S., Vassilev, A.O. et al. Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis 4, 14 (2004). https://doi.org/10.1186/1471-2334-4-14